Acalabrutinib (Calquence) Approved   For relapsed or refractory mantle cell lymphoma

Acalabrutinib (Calquence) Approved For relapsed or refractory mantle cell lymphoma

Annual-Meeting

1 year
227 Views
Share
Want to watch this again later?
Sign in to add this video to a playlist. Login
Report 0 0
Category:
Description:
Michelle Dawson, MD, AstraZeneca, talks about Acalabrutinib (Calquence) Approved For relapsed or refractory mantle cell lymphoma at Annual Meeting 2018.
Up Next Autoplay